8-K
filed December 12, 2025, 6:59 PM ET
ticker CYTK
CIK 0001061983
regulatory
confidence high
sentiment positive
materiality 0.80
CHMP recommends EU approval of Cytokinetics' MYQORZO for obstructive HCM
CYTOKINETICS INC
- CHMP adopted positive opinion recommending EU marketing authorization for MYQORZO (aficamten).
- Indicated for symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adults.
- European Commission final decision expected in Q1 2026.
- MYQORZO is a cardiac myosin inhibitor.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-25-316904
- form_type
- 8-K
- ticker
- CYTK
- cik
- 0001061983
- company_name
- CYTOKINETICS INC
- filed_at
- 2025-12-12T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:38.694607+00:00
- generated_at
- 2026-05-16T13:19:45.801371+00:00
- sec_items
- ["8.01"]
- event_type
- regulatory
- sentiment
- positive
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-25-316904
- json_url
- https://secwatch.observer/filing/0001193125-25-316904.json
- markdown_url
- https://secwatch.observer/filing/0001193125-25-316904.md
- text_url
- https://secwatch.observer/filing/0001193125-25-316904.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1061983/000119312525316904/0001193125-25-316904-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1061983/000119312525316904/cytk-20251212.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
LESL
Leslie's regains Nasdaq compliance for minimum market value of publicly held shares
Leslie's, Inc.
June 1, 2026, 4:28 PM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
OTLK
Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days
Outlook Therapeutics, Inc.
June 1, 2026, 9:15 AM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
SLXN
Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted
Silexion Therapeutics Corp
May 29, 2026, 7:00 AM ET
regulatory
Items 3.03, 5.03, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
RR
Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing
RICHTECH ROBOTICS INC.
May 28, 2026, 4:49 PM ET
regulatory
Items 3.01, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
MNKD
FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29
MANNKIND CORP
May 28, 2026, 8:37 AM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
SNAL
Snail receives Nasdaq extension to Sept 22, 2026 to regain listing compliance
Snail, Inc.
May 27, 2026, 4:25 PM ET
regulatory
Items 8.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
BBIO
FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026
BridgeBio Pharma, Inc.
May 27, 2026, 4:01 PM ET
regulatory
Items 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
JAGX
Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
Jaguar Health, Inc.
May 27, 2026, 9:10 AM ET
regulatory
Items 7.01, 8.01, 9.01
same SEC item: 8.01
same event type: regulatory
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.